Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM NASDAQ:CDT NASDAQ:GTBP NASDAQ:INDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$8.64-2.4%$9.10$0.06▼$14.93$6.60M0.98556,463 shs4,799 shsCDTConduit Pharmaceuticals$2.23+1.6%$3.36$2.13▼$622.50$1.78M1.97189,748 shs170,915 shsGTBPGT Biopharma$2.05+0.2%$2.71$1.72▼$4.10$6.69M1.48248,890 shs17,528 shsINDPIndaptus Therapeutics$11.64-1.8%$10.72$7.56▼$66.64$6.66M1.3563,533 shs6,363 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+0.73%-3.91%-3.17%-3.17%-77.88%CDTConduit Pharmaceuticals-3.52%-7.20%-4.78%-76.46%-99.42%GTBPGT Biopharma+2.00%-4.23%-27.66%-10.13%-28.17%INDPIndaptus Therapeutics-4.55%-9.60%+33.18%-12.52%-81.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.4671 of 5 stars3.50.00.00.02.60.00.0CDTConduit Pharmaceuticals0.4289 of 5 stars0.04.00.00.02.50.00.0GTBPGT Biopharma2.2375 of 5 stars3.81.00.00.03.80.00.6INDPIndaptus Therapeutics3.355 of 5 stars3.54.00.00.03.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.003,082.87% UpsideCDTConduit Pharmaceuticals 4.00Strong BuyN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00437.90% UpsideINDPIndaptus Therapeutics 3.00Buy$238.001,944.67% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K45.21N/AN/A$0.20 per share43.20CDTConduit PharmaceuticalsN/AN/AN/AN/A($73.54) per shareN/AGTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/ACDTConduit Pharmaceuticals-$17.80M-$534.48N/A∞N/AN/AN/A-435.57%8/11/2025 (Estimated)GTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)INDPIndaptus Therapeutics-$15.02M-$41.74N/AN/AN/AN/A-333.02%-216.36%8/11/2025 (Estimated)Latest CDT, INDP, AIM, and GTBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025GTBPGT Biopharma-$0.68N/AN/AN/AN/AN/A8/11/2025N/AINDPIndaptus Therapeutics-$0.36N/AN/AN/AN/AN/A5/15/2025Q1 2025CDTConduit PharmaceuticalsN/A-$19.80N/A-$1.32N/AN/A5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/A5/14/2025Q1 2025INDPIndaptus Therapeutics-$11.48-$8.96+$2.52-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ACDTConduit PharmaceuticalsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75CDTConduit PharmaceuticalsN/A1.311.31GTBPGT BiopharmaN/A0.730.73INDPIndaptus TherapeuticsN/A1.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%CDTConduit Pharmaceuticals3.29%GTBPGT Biopharma8.15%INDPIndaptus Therapeutics7.06%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%CDTConduit Pharmaceuticals7.72%GTBPGT Biopharma3.40%INDPIndaptus Therapeutics20.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableCDTConduit Pharmaceuticals3798,000736,000Not OptionableGTBPGT Biopharma83.27 million3.16 millionNo DataINDPIndaptus Therapeutics6572,000453,000Not OptionableCDT, INDP, AIM, and GTBP HeadlinesRecent News About These CompaniesIndaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and WarrantsJuly 1, 2025 | globenewswire.comIndaptus Therapeutics Announces Reverse Stock Split - FinanzNachrichten.deJune 26, 2025 | finanznachrichten.deIndaptus Therapeutics, Inc. Announces One-for-Twenty-Eight Reverse Stock Split to Enhance Nasdaq Compliance and Attract InvestorsJune 26, 2025 | nasdaq.comIndaptus Therapeutics Announces Reverse Stock SplitJune 25, 2025 | globenewswire.comIndaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding RoundJune 13, 2025 | quiverquant.comQIndaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and WarrantsJune 13, 2025 | globenewswire.comIndaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor TislelizumabJune 2, 2025 | globenewswire.comIndaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comIndaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development SummitMay 8, 2025 | globenewswire.comIndaptus Therapeutics, Inc. Common StockMarch 30, 2025 | fxempire.comFIndaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 SummitMarch 25, 2025 | globenewswire.comIndaptus Therapeutics reports new data on Phase 1 trial of Decoy20March 21, 2025 | markets.businessinsider.comIndaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20March 20, 2025 | globenewswire.comIndaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor TislelizumabMarch 18, 2025 | globenewswire.comIndaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last yearMarch 13, 2025 | markets.businessinsider.comIndaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate UpdateMarch 13, 2025 | globenewswire.comRegistration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025March 12, 2025 | globenewswire.comIndaptus Therapeutics expands patent portfolio in China, Japan, IsraelMarch 4, 2025 | markets.businessinsider.comIndaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer TreatmentsMarch 4, 2025 | globenewswire.comIndaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer SummitFebruary 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportBy Jeffrey Neal Johnson | July 13, 2025View 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportAlphabet: Technical Momentum Is Starting to TurnBy Ryan Hasson | July 10, 2025View Alphabet: Technical Momentum Is Starting to TurnQuantumScape Soars 30%: What Drove the Next-Gen EV Stock's RallyBy Leo Miller | June 27, 2025View QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's RallyAnalysts Bet Big on Uber Stock's Expansion in Autonomous DrivingBy Gabriel Osorio-Mazilli | July 14, 2025View Analysts Bet Big on Uber Stock's Expansion in Autonomous DrivingBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsBy Nathan Reiff | June 30, 2025View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsCDT, INDP, AIM, and GTBP Company DescriptionsAIM ImmunoTech NYSE:AIM$8.64 -0.21 (-2.37%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Conduit Pharmaceuticals NASDAQ:CDT$2.22 +0.04 (+1.60%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.GT Biopharma NASDAQ:GTBP$2.04 +0.01 (+0.25%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Indaptus Therapeutics NASDAQ:INDP$11.64 -0.21 (-1.77%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
